aTyr Pharma Shares Continue Downward Spiral Following Clinical Trial Failure

Fundamental Shift After Trial Results

The stock of biopharmaceutical company aTyr Pharma extended its decline in after-hours trading on Thursday, shedding nearly 6 percent. This persistent sell-off reflects continued investor anxiety in the wake of the failed EFZO-FIT Phase 3 clinical trial for its drug candidate, efzofitimod, in patients with pulmonary sarcoidosis.

On September 15, the company disclosed that its lead drug candidate had failed to meet the primary endpoint of the crucial study. The market’s reaction was swift and severe, erasing more than 80 percent of the stock’s value in a single day. The official data contained within the subsequent 8-K filing revealed disappointing figures.